Loading
STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.
Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signalling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerise and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Cisplatin and Picoplatin. Open Targets scores its association with cancer at 0.56 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.87, animal model 0.54, genetic association 0.03).
In plain words · STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.
STAT1 (Signal transducer and activator of transcription 1-alpha/beta) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer and Melanoma.
Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors.
No product in this corpus aims at STAT1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA STAT1: RNA low tissue specificity; high antibody staining in 1 normal tissue; highest cancer staining testis cancer (5 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Skin cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas STAT1 tissue; Open Targets ENSG00000115415 associations
First described 1992. Earliest sequence paper UniProt cites for the protein: Schindler et al, Proc. Natl. Acad. Sci. U.S.A, 1992, "Proteins of transcription factor ISGF-3: one gene encodes the 91- and 84-kDa ISGF-3 proteins that are activated by interferon alpha". Source.
Sources: HGNC HGNC:11362 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P42224 (protein name, function text, keywords and locations (REST API)); CIViC gene STAT1 (2 evidence items, 0 assertions, 2 variants; diseases: Melanoma, Ovarian Cancer (GraphQL API, CC0)); Open Targets ENSG00000115415 (association with cancer (MONDO_0004992) 0.56; (GraphQL API, CC0))
Signal transducer and transcription activator that mediates cellular responses to interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, signalling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerise and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state. Location: Cytoplasm; Nucleus (UniProt). Locus 2q32.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Appendix, Bone marrow, Lung, Lymph node, Pancreas, Prostate, Spleen, Testis.
Medium only: cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"STAT1" OR ABSTRACT:"STAT1" OR TITLE:"signal transducer and activator of transcription 1" OR ABSTRACT:"signal transducer and activator of transcription 1" OR TITLE:"Signal transducer and activator of transcription 1-alpha/beta" OR ABSTRACT:"Signal transducer and activator of transcription 1-alpha/beta" OR TITLE:"STAT91" OR ABSTRACT:"STAT91" OR TITLE:"ISGF-3" OR ABSTRACT:"ISGF-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about STAT1, not a curated reading list.
Shares JAK-STAT signalling, CIViC, Open Targets Platform.
Shares JAK-STAT signalling, Antigen presentation & immune editing, CIViC, Melanoma.
Shares JAK-STAT signalling, CIViC, Open Targets Platform.
Shares JAK-STAT signalling, CIViC, Open Targets Platform.
Shares Antigen presentation & immune editing, CIViC, Melanoma, Open Targets Platform.
Shares JAK-STAT signalling, CIViC, Ovarian cancer, Open Targets Platform.
Shares JAK-STAT signalling, Antigen presentation & immune editing.
Shares JAK-STAT signalling, Antigen presentation & immune editing.